Rashmi Ojha
Psychiatry · Columbus, NENPI 1407056476
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,050 of the $13,773 with a category attached, or 73.0%. Teva Pharmaceuticals USA, Inc. accounts for 74.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $8,092 and has fallen 87.4% since, to $1,021 in 2025. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $99.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- Alkermes, Inc.$745
- AbbVie$633
- Neurocrine Biosciences, Inc.$452
- Otsuka America Pharmaceutical, Inc.$451
- Johnson & Johnson$312
- plus $924 from 10 others
What the payments were for
- Consulting fees$10,05073%
- Food & beverage$3,55426%
- Education$1691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $10,257 |
| Alkermes, Inc. | 34 | $745 |
| AbbVie(2 entities) | 36 | $633 |
| Neurocrine Biosciences, Inc. | 6 | $452 |
| Otsuka America Pharmaceutical, Inc. | 13 | $451 |
| Johnson & Johnson | 9 | $312 |
| Axsome Therapeutics, Inc. | 5 | $182 |
| E.r. Squibb & Sons, L.L.C. | 5 | $182 |
| Harmony Biosciences LLC | 2 | $172 |
| Idorsia Pharmaceuticals US Inc | 2 | $136 |
| Lundbeck LLC | 4 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $63 |
| Ironshore Pharmaceuticals Inc. | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,773 in reported general payments places this provider in the 90th percentile of 160 psychiatry providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 47 | $628,232 |
| WakixPitolisant Hcl | 17 | $246,490 |
| IngrezzaValbenazine Tosylate | 12 | $109,743 |
| RexultiBrexpiprazole | 41 | $71,258 |
| Invega SustennaPaliperidone Palmitate | 19 | $66,538 |
| VraylarCariprazine Hcl | 21 | $30,567 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $22,490 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,428 |
| Aripiprazole | 170 | $11,056 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,257 |
| Clozapine | 110 | $8,926 |
| QuviviqDaridorexant Hcl | 11 | $6,034 |
| Varenicline Tartrate | 18 | $5,649 |
| Lisdexamfetamine Dimesylate | 16 | $4,606 |
| Duloxetine Hcl | 184 | $4,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $10,257 | $628,23247 claims |
| Harmony Biosciences LLCWakix | $172 | $246,49017 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $452 | $109,74312 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $451 | $71,25841 claims |
| Johnson & JohnsonInvega Sustenna | $312 | $66,53819 claims |
| AbbVieVraylar | $633 | $30,56721 claims |
| Axsome Therapeutics, Inc.Auvelity | $182 | $22,49020 claims |
| Alkermes, Inc.Lybalvi | $745 | $18,42811 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $136 | $6,03411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Columbus
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Navdeep SoodGrand Island$51K
- Walter DuffyLincoln$46K
- Dianna ClyneLincoln$19K
- Jeffrey CoffmanLincoln$18K
- Syed SattarOmaha$16K
- Michael SedlacekOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.